An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and thymosin beta-4. The panel turned down emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may aid treatment of antibiotic-resistant bacteria. Meanwhile, RFK Jr. advocated for expanded access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how policymakers view specialty peptide therapies, which have drawn increasing interest from consumers seeking alternatives to traditional drugs. Researchers say peptide treatments could alter approaches to difficult infections, though concerns about consistency persist. The committee's endorsement of four peptides clears a path for more expanded prescribing, even as watchdogs warn of long-term evidence. Sector observers note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, highlights the FDA's cautious stance on some peptide candidates.